Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 13/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 13/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8289163 | 0.94 | PTGS1 (0.62) | PTGS1PTGS2MEN1KMT2AP2RX7 | |
| SCHEMBL8289159 | 0.85 | PTGS1 (0.57) | PTGS1PTGS2 | |
| SCHEMBL8287004 | 0.84 | PTGS1 (0.61) | PTGS1PTGS2 | |
| SCHEMBL14516613 | 0.84 | PTGS1 (0.76) | PTGS1PTGS2MEN1KMT2A | |
| SCHEMBL8289162 | 0.83 | PTGS1 (0.60) | PTGS1PTGS2P2RX7 | |
| SCHEMBL14516172 | 0.82 | PTGS1 (0.76) | PTGS1PTGS2MEN1KMT2A | |
| SCHEMBL8291653 | 0.81 | PTGS1 (0.62) | PTGS1PTGS2P2RX7 | |
| SCHEMBL8287005 | 0.80 | PTGS1 (0.62) | PTGS1PTGS2PTGER4 | |
| SCHEMBL14497476 | 0.80 | PTGS1 (0.74) | PTGS1PTGS2MEN1KMT2A | |
| SCHEMBL8289164 | 0.80 | PTGS1 (0.63) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005046615-A2 | COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM MEDIATED DISORDERS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005037193-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR ADMINISTERED UNDER HYPOTHERMIC CONDITIONS FOR THE TREATMENT OF ISCHEMIC MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005018563-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A PHOSPHODIESTERASE INHIBITOR FOR THE TREATMENT OF ISCHEMIC MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018541-A2 | COX-2 INHIBITOR AND SEROTONIN MODULATOR FOR TREATING CNS DAMAGE | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005007156-A1 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004093816-A2 | COMPOSITIONS COMPRISING A SELECTIVE COX-2 INHIBITOR AND A CALCIUM MODULATING AGENT | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093814-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SODIUM CHANNEL BLOCKER | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093811-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SODIUM ION CHANNEL BLOCKER FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093813-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CALCIUM MODULATING AGENT FOR THE TREATMENT OF PAIN, INFLAMMATION OR INFLAMMATION MEDIATED DISORDERS | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |